当前位置: X-MOL 学术Clin. Appl. Thromb. Hemost. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Impact of Diabetes Mellitus on One-Year Clinical Outcomes in Patients Anticoagulated with Bivalirudin Undergoing Elective Percutaneous Coronary Intervention
Clinical and Applied Thrombosis/Hemostasis ( IF 2.9 ) Pub Date : 2022-08-09 , DOI: 10.1177/10760296221113344
Yulong Li 1 , Jiawen Li 1 , Changdong Guan 1 , Shuhong Su 2 , Zhifang Wang 2 , Haiwei Liu 3 , Bo Xu 1 , Weixian Yang 1 , Yuejin Yang 1 , Runlin Gao 1 , Jinqing Yuan 1 , Xueyan Zhao 1
Affiliation  

Background: Patients with diabetes mellitus (DM) are considered to increase the risk of thrombosis and bleeding. However, whether DM is an independent risk factor for events in patients anticoagulated with bivalirudin during elective percutaneous coronary intervention (PCI) is not clear. Methods: Patients anticoagulated with bivalirudin during elective PCI from January 2017 to August 2018 in 3 centers were enrolled. The primary endpoint of thrombotic events was major adverse cardiac and cerebrovascular events (MACCE, including all-cause death, myocardial infarction, ischemic revascularization, stent thrombosis, and stroke); the primary endpoint of bleeding events was Bleeding Academic Research Consortium (BARC) 2, 3 or 5 bleeding. Results: 1152 patients were finally enrolled. After one-year follow-up, 89 (7.7%) MACCE and 21 (1.8%) BARC 2, 3 or 5 bleeding occurred. Multivariate Cox regression analysis showed DM was not an independent risk factor for MACCE (hazard ratio [HR]: 1.029, 95% confidence interval [CI]: 0.674-1.573, P = .893), but peripheral artery disease (PAD) history (HR: 2.200, 95%CI: 1.290-3.751, P = .004) was an independent risk factor for MACCE. DM was not an independent risk factor for BARC 2, 3 or 5 bleeding (HR: 0.732, 95%CI: 0.293-1.831, P = .505), but PAD history (HR: 3.029, 95%CI: 1.102-8.332, P = .032) and low hemoglobin level (HR = 0.972, 95%CI: 0.947-0.998, P = .036) were independent risk factors for BARC 2, 3 or 5 bleeding. Conclusions: DM was not an independent risk factor for one-year thrombotic and bleeding events in patients anticoagulated with bivalirudin during elective PCI. More attention should be paid to PAD history and hemoglobin level to identify high-risk patients.



中文翻译:

糖尿病对接受选择性经皮冠状动脉介入治疗的比伐卢定抗凝患者一年临床结果的影响

背景:糖尿病(DM)患者被认为会增加血栓形成和出血的风险。然而,DM 是否是选择性经皮冠状动脉介入治疗 (PCI) 期间接受比伐卢定抗凝的患者事件的独立危险因素尚不清楚。方法:纳入 3 个中心 2017 年 1 月至 2018 年 8 月在择期 PCI 期间接受比伐卢定抗凝的患者。血栓事件的主要终点是主要不良心脑血管事件(MACCE,包括全因死亡、心肌梗死、缺血性血运重建、支架内血栓和中风);出血事件的主要终点是出血学术研究联盟 (BARC) 2、3 或 5 次出血。结果:最终入组了 1152 名患者。一年随访后,发生 89 例(7.7%)MACCE 和 21 例(1.8%)BARC 2、3 或 5 次出血。多变量 Cox 回归分析显示,DM 不是 MACCE 的独立危险因素(风险比 [HR]:1.029,95% 置信区间 [CI]:0.674-1.573,P  = .893),但外周动脉疾病(PAD)病史( HR: 2.200, 95%CI: 1.290-3.751, P  = .004) 是 MACCE 的独立危险因素。DM 不是 BARC 2、3 或 5 出血的独立危险因素(HR:0.732,95%CI:0.293-1.831,P  = .505),但 PAD 病史(HR:3.029,95%CI:1.102-8.332,P  = .032) 和低血红蛋白水平 (HR = 0.972, 95%CI: 0.947-0.998, P = .036) 是 BARC 2、3 或 5 级出血的独立危险因素。结论:在择期 PCI 期间使用比伐卢定抗凝的患者中,DM 不是一年血栓形成和出血事件的独立危险因素。应更多关注 PAD 病史和血红蛋白水平,以识别高危患者。

更新日期:2022-08-09
down
wechat
bug